Compare AbbVie Inc (ABBV) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Ross Stores, Inc. — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Ross Stores, Inc. trades at $216.42 (market cap $68.86B). The key difference: AbbVie Inc is far larger — about 6.5× Ross Stores, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | ROST | |
|---|---|---|
Market Cap | $449.91B | $68.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $240.13 |
52-Week Low | $184.85 | $127.59 |
Enterprise Value | $513.38B | $69.45B |
Dividend Yield | 2.72% | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Ross Stores (ROST) trades at $214.67, up 0.58% today, with strong fundamentals including 9.74% net income margin and 38.98% ROE. Recent earnings beats and a consensus price target of $259.00 suggest upside potential. Technicals are bearish near-term, but positive news highlights robust sales growth and expansion. Cash flow trends show volatility, with 2025 net cash flow negative but projected to rebound in 2026.
Outlook is positive driven by earnings momentum and store expansion, but risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is bullish with 64% buy ratings, supporting a growth-oriented view for investors seeking retail exposure with solid profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
